News
Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...
Eli Lilly's rare 40-year bond sparks talk of a Viking Therapeutics (VKTX) acquisition. Experts say LLY is "setting up for ...
Viking Therapeutics (VKTX) stock drops as its oral obesity drug VK2735 trails Novo's (NVO) oral Wegovy and Lilly's (LLY) ...
When bad news drops, investors have a tendency to sell first and ask questions later. Let's take a closer look at why Viking ...
Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.
Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.
Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback